USRE39096EExpiredUtility

Treatment of skin disorders

63
Assignee: HADASIT MED RES SERVICEPriority: Feb 11, 1997Filed: Apr 3, 2003Granted: May 16, 2006
Est. expiryFeb 11, 2017(expired)· nominal 20-yr term from priority
A61P 17/02A61K 31/517A61P 17/08A61P 17/06A61P 17/14A61P 17/10A61P 17/00
63
PatentIndex Score
1
Cited by
45
References
6
Claims

Abstract

An effective treatment for skin disorders characterized by abnormal skin cell behavior, including a pharmaceutically effective amount of Halofuginone. Skin disorders which can be treated include keloids, hypertrophic scars, psoriasis, acne, seborrhea and alopecia. Halofuginone can reduce or eliminate clinical symptoms of these disorders, as well as substantially prevent the formation of keloids and hypertrophic scars.

Claims

exact text as granted — not AI-modified
1. A method for the treatment of psoriasis in a subject, the method comprising the step of administering to the subject a pharmaceutically effective amount of a compound having a formula: 
                 
 
       wherein:
 n is  1  or  2 ;  
 R 1  is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;  
 R 2  is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and  
 R 3  is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl.  
 
     
     
       2. The method of  claim 1 , wherein said compound is Halofuginone. 
     
     
       3. The method of  claim 1 , wherein said compound is administered to the subject by a route selected from the group consisting of oral, parenteral and topical. 
     
     
       4. The method of  claim 3 , wherein said compound is administered to the subject by topical application. 
     
     
       5. The method of  claim 4 , wherein said compound is contained in a pharmaceutical carrier selected from the group consisting of a lotion, an ointment, a gel, a cream, a liquid and a spray. 
     
     
       6. The method of  claim 5 , wherein the step of administering said compound to the subject is performed until symptoms of psoriasis are absent in the subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.